HORIZON THERAPEUTICS PLC (HZNP)
IE00BQPVQZ61 - Common Stock
HORIZON THERAPEUTICS PLC
NASDAQ:HZNP (10/5/2023, 7:25:26 PM)
After market: 116.34 +0.04 (+0.03%)116.3
+0.05 (+0.04%)
Company Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 2,190 full-time employees. The company went IPO on 2010-08-11. The firm is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
Company Info
HORIZON THERAPEUTICS PLC
70 St. Stephen's Green, Saint Kevin's, Dublin 2
DUBLIN DUBLIN D04 C5Y6
P: 35317722100.0
CEO: Timothy Walbert
Employees: 2190
Website: https://www.horizontherapeutics.com/
HZNP News
11 days ago - InvestorPlace3 Stocks to Buy Low Today With High Hopes for TomorrowAmgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.
3 months ago - BloombergAmgen Expects a 2024 Sales Jump, Sets Sights on Obesity MarketAmgen Inc. expects revenue to jump as much as 20% this year, as the purchase of Horizon Therapeutics Plc buoys the company while it works to become a major competitor in the weight-loss drug market.
5 months ago - Seeking AlphaPfizer to close Seagen buyout this week as regulatory reviews complete (NYSE:PFE)Pfizer (PFE) receives necessary approvals to complete its acquisition of Seagen (SGEN) this week as it addresses antitrust concerns. Read more here.
5 months ago - Seeking AlphaTudor Investment opens new Seagen, AbbVie bets; exits Immersion, Lennox (NASDAQ:CME)Monica Schipper Tudor Investment, the hedge fund founded by billionaire Paul Tudor Jones, started new positions in Seagen (NASDAQ:SGEN), with 340K shares,...
6 months ago - BloombergMicrosoft-Activision Takeover Emboldens Merger Arb Traders to Boost Their BetsTraders who bet on corporate mergers and acquisitions are boosting their wagers on a slew of proposed deals, after successful trades on transactions like Microsoft Corp.’s purchase of Activision Blizzard Inc. have left them with more money to invest.
7 months ago - BloombergHedge Funds Won Big on Bets Amgen-Horizon Deal Would Go ThroughHedge funds Pentwater Capital Management, HBK Investments and Farallon Capital Management are reaping a windfall from bets that US regulators wouldn’t be able to stop Amgen Inc. from completing its $28 billion takeover of Horizon Therapeutics Plc.
HZNP Twits
Here you can normally see the latest stock twits on HZNP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
